BR0212211A - Diagnóstico de carcinomas - Google Patents

Diagnóstico de carcinomas

Info

Publication number
BR0212211A
BR0212211A BR0212211A BR0212211A BR0212211A BR 0212211 A BR0212211 A BR 0212211A BR 0212211 A BR0212211 A BR 0212211A BR 0212211 A BR0212211 A BR 0212211A BR 0212211 A BR0212211 A BR 0212211A
Authority
BR
Brazil
Prior art keywords
he4a
soluble
individual
detecting
provides
Prior art date
Application number
BR0212211A
Other languages
English (en)
Inventor
Michel Schummer
Ingegerd Hellstrom
Karl Erik Hellstrom
Jeffrey A Ledbetter
Martha Hayden-Ledbetter
Original Assignee
Pacific Northwest Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pacific Northwest Res Inst filed Critical Pacific Northwest Res Inst
Publication of BR0212211A publication Critical patent/BR0212211A/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"DIAGNóSTICO DE CARCINOMAS". A invenção conduz a composições e métodos para detecção de uma condição maligna, e refere-se a descoberta de formas solúveis e superficiais celulares de polipeptídeos HE4a, incluindo HE4a que é superexpressado em carcinomas ovarianos. Em particular, a invenção providencia uma seq³ência de ácido nucléico codificando HE4a, e também providencia um método de seleção critérios a quanto à presença de uma condição maligna num indivíduo, detectando a reatividade de um anticorpo específico para um polipeptídeo HE4a com uma molécula de ocorrência natural na forma solúvel e/ou de superfície celular numa amostra, de um tal indivíduo, e por seleção criteriosa de hibridização usando uma seq³ência de nucleotídeo de HE4a, bem como outras vantagens relacionadas.
BR0212211A 2001-08-29 2002-08-29 Diagnóstico de carcinomas BR0212211A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31653701P 2001-08-29 2001-08-29
PCT/EP2002/009653 WO2003021273A2 (en) 2001-08-29 2002-08-29 Diagnosis of carcinomas

Publications (1)

Publication Number Publication Date
BR0212211A true BR0212211A (pt) 2004-08-17

Family

ID=23229467

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0212211A BR0212211A (pt) 2001-08-29 2002-08-29 Diagnóstico de carcinomas

Country Status (12)

Country Link
US (4) US7270960B2 (pt)
EP (3) EP2913673B1 (pt)
JP (5) JP2005501549A (pt)
KR (1) KR20040062534A (pt)
CN (1) CN1813188A (pt)
BR (1) BR0212211A (pt)
CA (1) CA2459077C (pt)
ES (1) ES2628952T3 (pt)
HK (1) HK1214346A1 (pt)
MX (1) MXPA04001963A (pt)
RU (1) RU2004109149A (pt)
WO (1) WO2003021273A2 (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002071928A2 (en) * 2001-03-14 2002-09-19 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
US7270960B2 (en) * 2001-08-29 2007-09-18 Pacific Northwest Research Institute Diagnosis of ovarian carcinomas
CN1839205B (zh) * 2003-05-29 2012-05-16 千年药品公司 用于鉴定、评估、预防和治疗乳腺癌的组合物、试剂盒及方法
CA2536918A1 (en) 2003-08-26 2005-03-03 Leland Shapiro Compositions of, and methods for, alpha-1 antitrypsin fc fusion molecules
EP2261667A3 (en) * 2003-10-07 2011-05-25 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and their therapy of ovarian cancer
US20060014221A1 (en) * 2004-01-21 2006-01-19 Fujirebio Diagnostics, Inc. Detection of urinary mesothelin-/megakaryocyte potentiating factor-related peptides for assessment of mesothelioma
US20060014211A1 (en) * 2004-01-21 2006-01-19 Fujirebio Diagnostics, Inc. Detection of mesothelin-/megakaryocyte potentiating factor-related peptides for assessment of the peritoneum and the peritoneal cavity
WO2007011363A2 (en) * 2004-08-11 2007-01-25 Trubion Pharmaceuticals, Inc. Binding domain fusion proteins
WO2006119155A2 (en) * 2005-05-02 2006-11-09 The Brigham And Women's Hospital, Inc. Diagnostic serum antibody profiling
ATE438856T1 (de) * 2005-06-22 2009-08-15 Univ Johns Hopkins Biomarker für eierstockkrebs: mit ctap3 verwandte proteine
EP2423321A3 (en) 2006-01-04 2012-03-14 Fujirebio America, Inc. Use of HE4 and other biochemical markers for assessment of endometrial and uterine cancers
JP2009524438A (ja) * 2006-01-27 2009-07-02 トライパス イメージング インコーポレイテッド 卵巣癌を有する可能性の高い患者を同定するための方法およびそのための組成物
US7811778B2 (en) 2006-09-06 2010-10-12 Vanderbilt University Methods of screening for gastrointestinal cancer
EP2121761A1 (en) * 2007-03-09 2009-11-25 Tripath Imaging, Inc. He4 monoclonal antibodies and methods for their use
US8455189B2 (en) * 2007-03-29 2013-06-04 Jeffrey W. Allard Use of HE4 for assessment of breast cancers
US8642347B2 (en) * 2008-01-31 2014-02-04 The Brigham And Women's Hospital, Inc. Urinary CA125 peptides as biomarkers of ovarian cancer
US8476026B2 (en) * 2008-04-01 2013-07-02 The Brigham And Women's Hospital, Inc. Biomarkers of ovarian cancer
US8993347B2 (en) 2009-12-17 2015-03-31 Cornell University Methods for detecting antibodies in mucosal samples and device for sampling mucosal material
US20130095503A1 (en) * 2010-01-05 2013-04-18 University Of Cincinnati Serum spla2-iia as diagnosis marker for prostate and lung cancer
CA2809368C (en) * 2010-08-26 2021-08-24 University Of Washington Through Its Center For Commercialization Methods for detecting anti-he4 antibodies and methods of diagnosis and/or prognosis of conditions associated with he4-expressing cells
KR102074141B1 (ko) * 2011-02-17 2020-02-07 후지레비오 다이어그노스틱스, 인코포레이티드 ＨＥ4ａ의 결정을 위해 사용되는 조성물들 및 방법들
CN103582815A (zh) * 2011-02-24 2014-02-12 佛米利昂公司 用于卵巢癌的生物标志物组、诊断方法和测试试剂盒
WO2012170513A2 (en) * 2011-06-06 2012-12-13 Women & Infants' Hospital Of Rhode Island He4 based therapy for malignant disease
KR102103476B1 (ko) 2011-06-24 2020-04-23 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 알파-1 안티트립신 융합 분자용 조성물, 방법 및 용도
RU2639526C2 (ru) 2011-06-28 2017-12-21 ИНХИБРКС ЭлЭлСи Слитые полипептиды, содержащие домен wap, и способы их применения
US10400029B2 (en) 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
UA124083C2 (uk) 2011-06-28 2021-07-21 ІНГІБРЕКС, Інк. Злитий серпіновий поліпептид і спосіб його застосування
CN107011439B (zh) 2011-07-15 2020-11-10 卫材R&D管理有限公司 抗叶酸受体α抗体及其应用
EP2802653A4 (en) 2012-01-10 2015-09-02 Univ Colorado Regents ALPHA-1 ANTITRYPSIN FUSION MOLECULE COMPOSITIONS, METHODS AND USES THEREOF
CN103575902B (zh) * 2012-08-03 2015-07-29 河南生生医疗器械有限公司 一种时间分辨荧光法四项综合检测卵巢癌试剂盒及其应用
WO2016011143A1 (en) * 2014-07-15 2016-01-21 Temple University Of The Commonwealth System Of Higher Education Stabilized peptide fragments from redoxin proteins as cancer biomarkers
EP3339326A4 (en) * 2015-08-21 2019-01-09 Carsgen Therapeutics Limited ENTIRELY HUMAN ANTI-MESOTHELIN ANTIBODIES AND IMMUNE EFFECTIVE CELLS TARGETING THE MESOTHELIN
RU2641094C1 (ru) * 2016-12-22 2018-01-15 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова" Министерства здравоохранения Российской Федерации Способ ранней диагностики серозной карциномы яичника высокой степени злокачественности на основании изменения клеточного состава эпителия маточной трубы
WO2020018381A1 (en) 2018-07-18 2020-01-23 The Regents Of The University Of California Kidney injury treatment
JPWO2020203478A1 (pt) * 2019-04-02 2020-10-08
JPWO2021261483A1 (pt) * 2020-06-23 2021-12-30
EP4403634A1 (en) * 2021-09-16 2024-07-24 Qmine Co., Ltd. Antisense compound that regulates expression of wfdc2
WO2023043220A1 (ko) * 2021-09-16 2023-03-23 주식회사 큐마인 Wfdc2의 발현을 조절하는 안티센스 화합물

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4713352A (en) 1981-08-31 1987-12-15 Sloan-Kettering Institute For Cancer Reseach Monoclonal antibody panel for early diagnosis and therapy of renal carcinoma
US4612282A (en) 1981-12-15 1986-09-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Monoclonal antibodies reactive with human breast cancer
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
SE8300693L (sv) 1983-02-09 1984-08-10 Sven Lofdahl Sett att framstella och isolera proteiner och polypeptider samt en hybridvektor for detta
US4579827A (en) 1983-03-11 1986-04-01 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies to human gastrointestinal cancers and hybridoma method of production of the monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US5190931A (en) 1983-10-20 1993-03-02 The Research Foundation Of State University Of New York Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA
US4753894A (en) 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
JP2624470B2 (ja) 1984-10-02 1997-06-25 バイオジェン インコーポレイテッド ストレプトアビジン様ポリペプチドの製造
US5272254A (en) 1984-10-02 1993-12-21 Biogen Inc. Production of streptavidin-like polypeptides
ZA858371B (en) 1984-11-02 1987-03-25 Oncogen Monoclonal antibodies for human non-small cell lung carcinomas
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
ATE120761T1 (de) 1987-05-21 1995-04-15 Creative Biomolecules Inc Multifunktionelle proteine mit vorbestimmter zielsetzung.
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
GB8723661D0 (en) 1987-10-08 1987-11-11 British Bio Technology Synthetic gene
US5093245A (en) 1988-01-26 1992-03-03 Applied Biosystems Labeling by simultaneous ligation and restriction
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5087617A (en) 1989-02-15 1992-02-11 Board Of Regents, The University Of Texas System Methods and compositions for treatment of cancer using oligonucleotides
US5168053A (en) 1989-03-24 1992-12-01 Yale University Cleavage of targeted RNA by RNAase P
US5144019A (en) 1989-06-21 1992-09-01 City Of Hope Ribozyme cleavage of HIV-I RNA
US5272262A (en) 1989-06-21 1993-12-21 City Of Hope Method for the production of catalytic RNA in bacteria
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
DE4002981C2 (de) 1990-02-01 1998-03-12 Ihf Inst Fuer Hormon Und Fortp Humane, Epididymis-spezifische Polypeptide und deren Verwendung zur Therapie und Diagnose männlicher Infertilität
US5180818A (en) 1990-03-21 1993-01-19 The University Of Colorado Foundation, Inc. Site specific cleavage of single-stranded dna
US5135917A (en) 1990-07-12 1992-08-04 Nova Pharmaceutical Corporation Interleukin receptor expression inhibiting antisense oligonucleotides
US6072039A (en) 1991-04-19 2000-06-06 Rohm And Haas Company Hybrid polypeptide comparing a biotinylated avidin binding polypeptide fused to a polypeptide of interest
DE4135543A1 (de) 1991-10-28 1993-04-29 Boehringer Mannheim Gmbh Rekombinantes core-streptavidin
ES2252732T3 (es) * 1992-05-26 2006-05-16 Immunex Corporation Nueva citoquina que une cd30.
JPH07507449A (ja) 1992-05-29 1995-08-24 イー・アイ・デユポン・ドウ・ヌムール・アンド・カンパニー バチルススブチリス（Ｂａｃｉｌｌｕｓｓｕｂｔｉｌｉｓ）からのストレプトアビジンの産生
US5935824A (en) * 1996-01-31 1999-08-10 Technologene, Inc. Protein expression system
US6313269B1 (en) 1997-03-14 2001-11-06 Smithkline Beecham Corporation Tumor necrosis factor related receptor, TR6
EP1033402A4 (en) 1997-11-05 2003-01-02 Sumitomo Electric Industries P16 BINDING PROTEINS, GENE OF SUCH PROTEINS AND ANTIBODIES AGAINST THESE PROTEINS
US6783961B1 (en) * 1999-02-26 2004-08-31 Genset S.A. Expressed sequence tags and encoded human proteins
GB9810040D0 (en) * 1998-05-11 1998-07-08 Univ Nottingham Blood borne tumour markers
CA2349444A1 (en) * 1998-11-03 2000-05-11 Mitokor Production of adenine nucleotide translocator (ant), novel ant ligands and screening assays therefor
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
CA2369433A1 (en) 1999-02-26 2000-08-31 Pacific Northwest Research Institute Methods and compositions for diagnosing carcinomas
CA2296792A1 (en) 1999-02-26 2000-08-26 Genset S.A. Expressed sequence tags and encoded human proteins
US6770445B1 (en) * 1999-02-26 2004-08-03 Pacific Northwest Research Institute Methods and compositions for diagnosing carcinomas
US20030143234A1 (en) 1999-08-20 2003-07-31 Wenyuan Shi Anti-microbial targeting chimeric pharmaceutical
CA2382783A1 (en) * 1999-08-24 2001-03-01 Texas Biotechnology Corporation A polynucleotide encoding a human junctional adhesion protein (jam-2)
WO2001016354A1 (en) 1999-09-02 2001-03-08 Gene Logic, Inc. Modulation of he4 in inflammatory and renal diseases
AU7701100A (en) * 1999-09-03 2001-04-10 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
CA2392757A1 (en) 2000-01-31 2001-08-02 Human Genome Sciences Inc. Nucleic acids, proteins, and antibodies
WO2001075177A2 (en) * 2000-04-03 2001-10-11 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Tumor markers in ovarian cancer
AU2001266787A1 (en) 2000-06-07 2002-01-08 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US20020182619A1 (en) * 2000-11-08 2002-12-05 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
WO2002071928A2 (en) 2001-03-14 2002-09-19 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
EP1390497A2 (en) * 2001-05-25 2004-02-25 Genset Human cdnas and proteins and uses thereof
US7270960B2 (en) 2001-08-29 2007-09-18 Pacific Northwest Research Institute Diagnosis of ovarian carcinomas
JP2006515065A (ja) 2002-08-16 2006-05-18 ディシジョン バイオマーカーズ インコーポレイテッド 蛍光配列の読み取り
WO2004063355A2 (en) 2003-01-10 2004-07-29 Protein Design Labs, Inc. Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer
CA2557438C (en) * 2004-02-19 2017-01-17 Yale University Identification of cancer protein biomarkers using proteomic techniques
DE102004014645A1 (de) * 2004-03-25 2005-10-13 Mitsubishi Polyester Film Gmbh Transparente, elektrisch leitfähige, beschichtete Polyesterfolie, Verfahren zu ihrer Herstellung sowie ihre Verwendung
WO2007011363A2 (en) * 2004-08-11 2007-01-25 Trubion Pharmaceuticals, Inc. Binding domain fusion proteins
DE602006002809D1 (de) 2005-02-16 2008-10-30 Dana Farber Cancer Inst Inc Verfahren zur erkennung eines ovarialkarzinoms
WO2006135886A2 (en) 2005-06-13 2006-12-21 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2007002535A2 (en) 2005-06-24 2007-01-04 Ciphergen Biosystems, Inc. Biomarkers for ovarian cancer
EP2423321A3 (en) 2006-01-04 2012-03-14 Fujirebio America, Inc. Use of HE4 and other biochemical markers for assessment of endometrial and uterine cancers
EP2087152B1 (en) * 2006-10-27 2015-03-11 Walfish, Paul Endometrial biomarkers
EP2121761A1 (en) * 2007-03-09 2009-11-25 Tripath Imaging, Inc. He4 monoclonal antibodies and methods for their use
CA2809368C (en) * 2010-08-26 2021-08-24 University Of Washington Through Its Center For Commercialization Methods for detecting anti-he4 antibodies and methods of diagnosis and/or prognosis of conditions associated with he4-expressing cells
KR102074141B1 (ko) * 2011-02-17 2020-02-07 후지레비오 다이어그노스틱스, 인코포레이티드 ＨＥ4ａ의 결정을 위해 사용되는 조성물들 및 방법들

Also Published As

Publication number Publication date
JP2012161317A (ja) 2012-08-30
CA2459077C (en) 2018-06-05
ES2628952T3 (es) 2017-08-04
EP2913673B1 (en) 2017-05-31
JP2005501549A (ja) 2005-01-20
WO2003021273A3 (en) 2003-12-04
KR20040062534A (ko) 2004-07-07
US9090712B2 (en) 2015-07-28
JP2016065870A (ja) 2016-04-28
US20100047818A1 (en) 2010-02-25
JP2009195240A (ja) 2009-09-03
WO2003021273A2 (en) 2003-03-13
MXPA04001963A (es) 2005-02-17
US7270960B2 (en) 2007-09-18
EP2322933A1 (en) 2011-05-18
HK1214346A1 (zh) 2016-07-22
EP1421388A2 (en) 2004-05-26
RU2004109149A (ru) 2005-05-10
US20090104684A1 (en) 2009-04-23
EP2913673A1 (en) 2015-09-02
JP5797136B2 (ja) 2015-10-21
CA2459077A1 (en) 2003-03-13
JP2014081386A (ja) 2014-05-08
US20030108965A1 (en) 2003-06-12
US20160033512A1 (en) 2016-02-04
CN1813188A (zh) 2006-08-02
JP5188443B2 (ja) 2013-04-24

Similar Documents

Publication Publication Date Title
BR0212211A (pt) Diagnóstico de carcinomas
Peng et al. New prognosis biomarkers identified by dynamic proteomic analysis of colorectal cancer
WO2004076679A3 (en) Serum macrophage migration inhibitory factor (mif) as marker for prostate cancer
EP2154245A3 (en) Composition and method for diagnosing kidney cancer and for predicting prognosis for kidney cancer patient
EP1708745A4 (en) ANTIBODIES FOR ONCOGEN STRAINS OF HPV AND METHODS OF USE
WO2008012362A3 (en) New protein isoforms and uses thereof
WO2009019365A3 (fr) Procede de dosage de l'ezrine pour le diagnostic in vitro du cancer colorectal
WO2005103719A3 (en) Using plasma proteomic pattern for diagnosis, classification, prediction of response to therapy and clinical behavior, stratification of therapy, and monitoring disease in hematologic malignancies
ATE474857T1 (de) Antikörper gegen ein epitop auf agr2, assays und hybridome
EP1399739A4 (en) METHOD AND KITS FOR DIAGNOSIS OF TUMOR ENGENITATION AND DETERMINATION OF RESISTANCE TO THE ANTINEOPLASTIC EFFECTS OF ANTI-STROGEN THERAPY
DE502006003717D1 (de) Bestimmung von kurzkettiger srl-alkoholdehydrogenase (dhrs4) als biomarker für entzündungen und infektionen
Malinowsky et al. UPA and PAI-1 analysis from fixed tissues-new perspectives for a known set of predictive markers
BRPI0607016A2 (pt) marcadores polipeptìdicos para o diagnóstico de cáncer de próstata
ATE318935T1 (de) Bewertungssystem für die vorhersage von krebsrezidiven
NO20013563L (no) Fremgangsmåter og prövesett for sekvensering av polypeptider
Capello et al. Phosphorylated alpha-enolase induces autoantibodies in HLA-DR8 pancreatic cancer patients and triggers HLA-DR8 restricted T-cell activation
DE60328186D1 (de) Zusammensetzung für die herstellung von histologischen, autopsischen und zytologischen proben
BR0210094A (pt) Método para medir a proporção de expressão de um gene da classe de genes padrões
US8257716B2 (en) Anti-PDEF antibodies and uses thereof
HK1112630A1 (en) Antibodies against april as biomarkers for early prognosis of lymphoma patients
CN105399805B (zh) 木瓜功能着丝粒抗原多肽及其应用
AR023904A1 (es) Anticuerpos para el antigeno de las celulas dendriticas y sus usos
DE60012723D1 (de) Verfahren zur bestimmung von disaccharidasen
DE60334408D1 (de) Nsäuren
SE0100595D0 (sv) Immunological detection of prostate diseases and prostatic-related diseases

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired